Hegedüs, L.; Livingstone, E.; Bánkfalvi, Á.; Viehof, J.; Enyedi, Á.; Bilecz, Á.; Győrffy, B.; Baranyi, M.; Tőkés, A.-M.; Gil, J.;
et al. The Prognostic Relevance of PMCA4 Expression in Melanoma: Gender Specificity and Implications for Immune Checkpoint Inhibition. Int. J. Mol. Sci. 2022, 23, 3324.
https://doi.org/10.3390/ijms23063324
AMA Style
Hegedüs L, Livingstone E, Bánkfalvi Á, Viehof J, Enyedi Á, Bilecz Á, Győrffy B, Baranyi M, Tőkés A-M, Gil J,
et al. The Prognostic Relevance of PMCA4 Expression in Melanoma: Gender Specificity and Implications for Immune Checkpoint Inhibition. International Journal of Molecular Sciences. 2022; 23(6):3324.
https://doi.org/10.3390/ijms23063324
Chicago/Turabian Style
Hegedüs, Luca, Elisabeth Livingstone, Ágnes Bánkfalvi, Jan Viehof, Ágnes Enyedi, Ágnes Bilecz, Balázs Győrffy, Marcell Baranyi, Anna-Mária Tőkés, Jeovanis Gil,
and et al. 2022. "The Prognostic Relevance of PMCA4 Expression in Melanoma: Gender Specificity and Implications for Immune Checkpoint Inhibition" International Journal of Molecular Sciences 23, no. 6: 3324.
https://doi.org/10.3390/ijms23063324
APA Style
Hegedüs, L., Livingstone, E., Bánkfalvi, Á., Viehof, J., Enyedi, Á., Bilecz, Á., Győrffy, B., Baranyi, M., Tőkés, A.-M., Gil, J., Marko-Varga, G., Griewank, K. G., Zimmer, L., Váraljai, R., Sucker, A., Zaremba, A., Schadendorf, D., Aigner, C., & Hegedüs, B.
(2022). The Prognostic Relevance of PMCA4 Expression in Melanoma: Gender Specificity and Implications for Immune Checkpoint Inhibition. International Journal of Molecular Sciences, 23(6), 3324.
https://doi.org/10.3390/ijms23063324
